NCT03875495 · ADVERSE EVENTS

Adverse events

A Phase I/II Study Evaluating Temferon in Multiple Myeloma Patients With Early Relapse After Front Line Therapy (TEM-MM) · Source last updated 2022-01-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Adverse events occurred during the study; they are not necessarily caused by treatment. Serious events are not interchangeable with severe/grade 3–4 events. These safety populations may differ from efficacy populations.

Collection time frame: No patients received Temferon
Other-event reporting threshold: 0%

No treatment related adverse events were reported as Temferon was not adminsitered

Participants affected / participants at risk, as reported
Safety group	Serious events	Other events	Deaths
Untreated Patients 3 patients recruited but did not receive Temferon	0 / 0	0 / 0	0 / 0

Group identifiers: EG000: Untreated Patients

Serious adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

Other reported adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

Complete source fields

description

No treatment related adverse events were reported as Temferon was not adminsitered

event Groups

deaths Num Affected
0
deaths Num At Risk
0
description
3 patients recruited but did not receive Temferon
id
EG000
other Num Affected
0
other Num At Risk
0
serious Num Affected
0
serious Num At Risk
0
title
Untreated Patients

frequency Threshold

time Frame

No patients received Temferon

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice